Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its target price upped by analysts at Barclays PLC in a research report issued to clients and investors on Thursday. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently issued reports on ALNY. BMO Capital Markets started coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, April 17th. They issued an “outperform” rating and a $73.00 target price for the company. Chardan Capital set a $95.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, May 5th. Morgan Stanley lifted their target price on shares of Alnylam Pharmaceuticals from $39.00 to $42.00 and gave the company an “equal weight” rating in a research note on Monday, May 8th. Credit Suisse Group reiterated a “hold” rating and issued a $50.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 9th. Finally, Piper Jaffray Companies set a $118.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 15th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $79.79.

Alnylam Pharmaceuticals (ALNY) traded down 3.14% during midday trading on Thursday, hitting $77.99. 344,720 shares of the stock traded hands. Alnylam Pharmaceuticals has a 1-year low of $31.38 and a 1-year high of $86.92. The company has a 50-day moving average price of $81.35 and a 200-day moving average price of $61.53. The firm’s market cap is $6.72 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.12. The business had revenue of $15.93 million during the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. Alnylam Pharmaceuticals’s revenue was up 82.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.05) earnings per share. Analysts predict that Alnylam Pharmaceuticals will post ($5.21) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/10/barclays-plc-boosts-alnylam-pharmaceuticals-inc-alny-price-target-to-0-00.html.

In other Alnylam Pharmaceuticals news, VP Michael Mason sold 9,375 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the sale, the vice president now owns 5,625 shares in the company, valued at $393,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Sanofi purchased 297,501 shares of the firm’s stock in a transaction on Wednesday, May 31st. The shares were acquired at an average price of $71.87 per share, for a total transaction of $21,381,396.87. The disclosure for this purchase can be found here. Insiders have sold 64,125 shares of company stock worth $4,325,000 in the last quarter. Corporate insiders own 4.30% of the company’s stock.

A number of large investors have recently bought and sold shares of ALNY. PNC Financial Services Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock valued at $446,000 after buying an additional 36 shares in the last quarter. State of Wisconsin Investment Board increased its stake in shares of Alnylam Pharmaceuticals by 0.7% in the second quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 100 shares in the last quarter. Prudential Financial Inc. increased its stake in shares of Alnylam Pharmaceuticals by 4.8% in the second quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 200 shares in the last quarter. Utah Retirement Systems increased its stake in shares of Alnylam Pharmaceuticals by 1.5% in the second quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock valued at $1,100,000 after buying an additional 200 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in shares of Alnylam Pharmaceuticals by 4.7% in the second quarter. Bank of Montreal Can now owns 9,974 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 446 shares in the last quarter. Hedge funds and other institutional investors own 88.96% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.